These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 4436423)

  • 1. Glucose intolerance in Parkinson's disease.
    Lipman IJ; Boykin ME; Flora RE
    J Chronic Dis; 1974 Dec; 27(11-12):573-9. PubMed ID: 4436423
    [No Abstract]   [Full Text] [Related]  

  • 2. Glucose, insulin, and free fatty acid metabolism in Parkinson's disease treated with levodopa.
    Van Woert MH; Mueller PS
    Clin Pharmacol Ther; 1971; 12(2):360-7. PubMed ID: 5577484
    [No Abstract]   [Full Text] [Related]  

  • 3. Metabolic responses to acute and chronic L-dopa administration in patients with parkinsonism.
    Sirtori CR; Bolme P; Azarnoff DL
    N Engl J Med; 1972 Oct; 287(15):729-33. PubMed ID: 5056733
    [No Abstract]   [Full Text] [Related]  

  • 4. [Significance of disorders of glucose metabolism in diseases of the nervous system (author's transl)].
    Glasner H
    Munch Med Wochenschr; 1973 Dec; 115(49):2225-8. PubMed ID: 4801588
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of long-term L-dopa therapy on carbohydrate metabolism in patients with Parkinson's disease.
    Rosati G; Maioli M; Aiello I; Farris A; Agnetti V
    Eur Neurol; 1976; 14(3):229-39. PubMed ID: 1278195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dementia is associated with insulin resistance in patients with Parkinson's disease.
    Bosco D; Plastino M; Cristiano D; Colica C; Ermio C; De Bartolo M; Mungari P; Fonte G; Consoli D; Consoli A; Fava A
    J Neurol Sci; 2012 Apr; 315(1-2):39-43. PubMed ID: 22265943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abnormal insulin secretion in Parkinson's disease before and during L-dihydroxyphenylalanine (L-dopa) therapy.
    Van Woert MH; Mueller PS; Ambani LM; Rathey U
    J Endocrinol; 1973 Dec; 59(3):523-34. PubMed ID: 4761683
    [No Abstract]   [Full Text] [Related]  

  • 8. [Use of the oral glucose tolerance curve as a criterion for validating some indicators of risk of developing glucose intolerance].
    González Bernal G; Avila Rosas H; Breña Flores H
    Rev Invest Clin; 1988; 40(3):259-64. PubMed ID: 3217617
    [No Abstract]   [Full Text] [Related]  

  • 9. Apomorphine increases blood glucose concentrations in Parkinson's disease.
    Tison F; Fouillet N; Henry P
    Clin Neuropharmacol; 1994 Feb; 17(1):92-5. PubMed ID: 8149364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endocrine function and glucose metabolism in patients with Parkinson's disease and their alternation by L-Dopa.
    Boyd AE; Lebovitz HE; Feldman JM
    J Clin Endocrinol Metab; 1971 Nov; 33(5):829-37. PubMed ID: 5125386
    [No Abstract]   [Full Text] [Related]  

  • 11. Glucose intolerance and cardiovascular disease.
    Epstein FH
    Triangle; 1973; 12(1):3-8. PubMed ID: 4577561
    [No Abstract]   [Full Text] [Related]  

  • 12. Azotemia and glucose intolerance.
    Cerletty JM; Engbring NH
    Ann Intern Med; 1967 Jun; 66(6):1097-108. PubMed ID: 6027945
    [No Abstract]   [Full Text] [Related]  

  • 13. Cerebral glucose utilization in Parkinson's disease.
    Sandyk R; Gillman MA
    J Neurol Neurosurg Psychiatry; 1985 May; 48(5):489. PubMed ID: 3998760
    [No Abstract]   [Full Text] [Related]  

  • 14. Gastric emptying, postprandial blood pressure, glycaemia and splanchnic flow in Parkinson's disease.
    Trahair LG; Kimber TE; Flabouris K; Horowitz M; Jones KL
    World J Gastroenterol; 2016 May; 22(20):4860-7. PubMed ID: 27239112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebral glucose metabolism in Parkinson's disease.
    Martin WR; Beckman JH; Calne DB; Adam MJ; Harrop R; Rogers JG; Ruth TJ; Sayre CI; Pate BD
    Can J Neurol Sci; 1984 Feb; 11(1 Suppl):169-73. PubMed ID: 6608981
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of intravenous infusion of L-DOPA on plasma growth hormone levels in man.
    Imura H; Nakai Y; Matsukura S; Matsuyama H
    Horm Metab Res; 1973 Jan; 5(1):41-5. PubMed ID: 4706921
    [No Abstract]   [Full Text] [Related]  

  • 17. [Lipid metabolism in Parkinson's disease].
    Vasilenko AF; Shamurov IuS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2012; 112(7):65-7. PubMed ID: 23011437
    [No Abstract]   [Full Text] [Related]  

  • 18. NADPH oxidases 2 activation in patients with Parkinson's disease.
    Marrali G; Casale F; Salamone P; Fuda G; Ilardi A; Manera U; Calvo A; Zibetti M; Lopiano L; Chiò A
    Parkinsonism Relat Disord; 2018 Apr; 49():110-111. PubMed ID: 29331562
    [No Abstract]   [Full Text] [Related]  

  • 19. [Glucose metabolism and blood flow studies in 2 cases with juvenile Parkinson's disease].
    Shibasaki T
    Nihon Rinsho; 1997 Jan; 55(1):95-100. PubMed ID: 9014429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbohydrate metabolism in lichen planus.
    Lowe NJ; Cudworth AG; Clough SA; Bullen MF
    Br J Dermatol; 1976 Jul; 95(1):9-12. PubMed ID: 952747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.